References
Atkinson TP, Duffy LB, Pendley D, Dai Y, Cassell GH: Deficient immune response to Mycoplasma pneumoniae in childhood asthma. Allergy Asthma Proc. 2009, 30: 158-65. 10.2500/aap.2009.30.3207.
Kannan TR, Baseman JB: ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A. 2006, 103: 6724-9. 10.1073/pnas.0510644103. Epub 2006 Apr 14
Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR, Coalson JJ, Baseman JB, Hardy RD: Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains. Am J Respir Crit Care Med. 2010, 182: 797-804. 10.1164/rccm.201001-0080OC. Epub 2010 May 27
Medina JL, Coalson JJ, Brooks EG, Winter VT, Chaparro A, Principe MF, Kannan TR, Baseman JB, Dube PH: Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol. 2012, 46: 815-22. 10.1165/rcmb.2011-0135OC. Epub 2012 Jan 26
Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N, Hardy RD: The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008, 198: 1180-1188. 10.1086/591915.
Morozumi M, Takahashi T, Ubukata K: Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010, 16: 78-86. 10.1007/s10156-009-0021-4. Epub 2010 Jan 22. Review
Principi N, Esposito S: Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013, 68: 506-11. 10.1093/jac/dks457. Epub 2012 Nov 20. Review